The IsoPSA prostate-specific antigen test could reduce unnecessary prostate biopsies by more than 40% while reliably differentiating among high-grade, low-grade and benign disease, a new validation study has found.
Innovative diagnostic tools and treatments are refining management of prostate cancer, and helping clinicians and patients make better decisions.
Rather than abandoning routine prostate-specific antigen-based prostate cancer screening – a move that may have contributed to a recent rise in metastatic cancers – the right approach is to strategically use PSA and other diagnostic tools, says Glickman Urological & Kidney Institute Chairman Eric Klein, MD.
The novel IsoPSA test can reliably discriminate structural changes in the prostate specific antigen protein, which correlates with the presence or absence of cancer. A prospective trial also shows the test has the potential to differentiate patients at risk for high- grade disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Using the new 4Kscore test after a positive result from a traditional PSA test can reduce the number of prostate biopsies by 30 to 50 percent while still accurately identifying high-grade cancers.